Analysts See 100% Upside To Rigel After Tavalisse Approval
April 18, 2018 at 13:23 PM EDT
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.